| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
ABIA: maintaining interest in HIV in Brazil
|
Daniels, Joe Parkin
|
|
2019
|
|
10 |
p. e652
|
artikel
|
| 2 |
Access to opioid agonist therapy in Russia: time for reform
|
Zelenev, Alexei
|
|
2018
|
|
10 |
p. e542-e543
|
artikel
|
| 3 |
Acción Solidaria: propping up HIV treatment in Venezuela
|
Daniels, Joe Parkin
|
|
2018
|
|
10 |
p. e549
|
artikel
|
| 4 |
Adolescent retention in HIV care within differentiated service-delivery models in sub-Saharan Africa
|
Maskew, Mhairi
|
|
|
|
10 |
p. e726-e734
|
artikel
|
| 5 |
Advancing bnAb combinations for HIV prevention
|
Gruell, Henning
|
|
|
|
10 |
p. e625-e626
|
artikel
|
| 6 |
Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial
|
Velloza, Jennifer
|
|
|
|
10 |
p. e680-e689
|
artikel
|
| 7 |
17 alpha-hydroxyprogesterone caproate, HIV, and preterm birth
|
Ntozini, Robert
|
|
|
|
10 |
p. e600-e601
|
artikel
|
| 8 |
A map to a better tomorrow
|
De Ambrogi, Marco
|
|
2018
|
|
10 |
p. e551
|
artikel
|
| 9 |
Anti-inflammatory therapy in well controlled HIV infection
|
Tarr, Philip E
|
|
2018
|
|
10 |
p. e538-e539
|
artikel
|
| 10 |
Anti-LGBT laws continue to hinder the HIV response
|
The Lancet HIV,
|
|
|
|
10 |
p. e667
|
artikel
|
| 11 |
Antiretroviral switch studies do matter
|
Daar, Eric S
|
|
2018
|
|
10 |
p. e546
|
artikel
|
| 12 |
Art and activism in New York
|
Martin, Colin
|
|
2019
|
|
10 |
p. e653-e654
|
artikel
|
| 13 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial
|
Avihingsanon, Anchalee
|
|
|
|
10 |
p. e640-e652
|
artikel
|
| 14 |
BMS-663068, a safe and effective HIV-1 attachment inhibitor
|
Ballana, Ester
|
|
2015
|
|
10 |
p. e404-e405
nvt p.
|
artikel
|
| 15 |
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
|
Maggiolo, Franco
|
|
2019
|
|
10 |
p. e655-e666
|
artikel
|
| 16 |
Bringing history to life: Los Angeles' response to HIV/AIDS
|
Burki, Talha
|
|
|
|
10 |
p. e638
|
artikel
|
| 17 |
Cancer risk in adolescents and young adults living with HIV in South Africa: a nationwide cohort study
|
Ruffieux, Yann
|
|
|
|
10 |
p. e614-e622
|
artikel
|
| 18 |
Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis
|
Ford, Nathan
|
|
2015
|
|
10 |
p. e438-e444
nvt p.
|
artikel
|
| 19 |
Changing landscapes for HIV in Malaysia
|
Barmania, Sima
|
|
|
|
10 |
p. e675-e676
|
artikel
|
| 20 |
Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use
|
Mbuagbaw, Lawrence
|
|
|
|
10 |
p. e684-e689
|
artikel
|
| 21 |
Cities getting to 90-90-90 and beyond
|
The Lancet HIV,
|
|
2019
|
|
10 |
p. e639
|
artikel
|
| 22 |
Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial
|
Leth, Steffen
|
|
2016
|
|
10 |
p. e463-e472
nvt p.
|
artikel
|
| 23 |
Community-wide HIV testing, linkage case management, and defaulter tracing in Bukoba, Tanzania: pre-intervention and post-intervention, population-based survey evaluation
|
Steiner, Claire
|
|
|
|
10 |
p. e699-e710
|
artikel
|
| 24 |
Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis
|
Kanters, Steve
|
|
2017
|
|
10 |
p. e433-e441
|
artikel
|
| 25 |
Conditional economic incentives to improve HIV prevention and treatment in low-income and middle-income countries
|
Galárraga, Omar
|
|
2019
|
|
10 |
p. e705-e714
|
artikel
|
| 26 |
Corrections
|
|
|
2015
|
|
10 |
p. e416-
1 p.
|
artikel
|
| 27 |
Corrections
|
|
|
2015
|
|
10 |
p. e416-
1 p.
|
artikel
|
| 28 |
Corrections
|
|
|
2016
|
|
10 |
p. e460-
1 p.
|
artikel
|
| 29 |
Correction to Lancet HIV 2018; DOI:10.1016/S2352-3018(18)30092-4
|
|
|
2018
|
|
10 |
p. e545
|
artikel
|
| 30 |
Correction to Lancet HIV 2018; 5: e488–97
|
|
|
2018
|
|
10 |
p. e545
|
artikel
|
| 31 |
Correction to Lancet HIV 2018; 5: e438–47
|
|
|
2018
|
|
10 |
p. e545
|
artikel
|
| 32 |
Cost-effectiveness of early identification of HIV infection
|
Nichols, Brooke E
|
|
2017
|
|
10 |
p. e431-e432
|
artikel
|
| 33 |
Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis
|
Baggaley, Rebecca F
|
|
2017
|
|
10 |
p. e465-e474
|
artikel
|
| 34 |
Curbing HIV incidence in people who inject drugs
|
Malyuta, Ruslan
|
|
2016
|
|
10 |
p. e453-e454
nvt p.
|
artikel
|
| 35 |
Data-driven HIV programming to maximise health benefits
|
Barnabas, Ruanne V
|
|
|
|
10 |
p. e662-e663
|
artikel
|
| 36 |
Development and validation of an automated HIV prediction algorithm to identify candidates for pre-exposure prophylaxis: a modelling study
|
Krakower, Douglas S
|
|
2019
|
|
10 |
p. e696-e704
|
artikel
|
| 37 |
Differences in healthy longevity by HIV status and viral load among older South African adults: an observational cohort modelling study
|
Payne, Collin F
|
|
|
|
10 |
p. e709-e716
|
artikel
|
| 38 |
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon
|
Calmy, Alexandra
|
|
|
|
10 |
p. e677-e687
|
artikel
|
| 39 |
Dolutegravir dosing with rifampicin
|
Cattaneo, Dario
|
|
|
|
10 |
p. e635-e636
|
artikel
|
| 40 |
Dolutegravir dosing with rifampicin – Authors' reply
|
Maartens, Gary
|
|
|
|
10 |
p. e636
|
artikel
|
| 41 |
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
|
Venter, Willem D F
|
|
|
|
10 |
p. e666-e676
|
artikel
|
| 42 |
Drug-level feedback counselling: modest support to PrEP adherence
|
Hensen, Bernadette
|
|
|
|
10 |
p. e668-e669
|
artikel
|
| 43 |
Drug supply crisis in Venezuela
|
Daniels, Joe Parkin
|
|
2018
|
|
10 |
p. e547-e548
|
artikel
|
| 44 |
Dynamics of the HIV outbreak and response in Scott County, IN, USA, 2011–15: a modelling study
|
Gonsalves, Gregg S
|
|
2018
|
|
10 |
p. e569-e577
|
artikel
|
| 45 |
Effect of a conditional cash transfer programme on AIDS incidence, hospitalisations, and mortality in Brazil: a longitudinal ecological study
|
de Sampaio Morais, Gabriel Alves
|
|
|
|
10 |
p. e690-e699
|
artikel
|
| 46 |
Effect of low-threshold methadone maintenance therapy for people who inject drugs on HIV incidence in Vancouver, BC, Canada: an observational cohort study
|
Ahamad, Keith
|
|
2015
|
|
10 |
p. e445-e450
nvt p.
|
artikel
|
| 47 |
Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study
|
Heffron, Renee
|
|
2017
|
|
10 |
p. e449-e456
|
artikel
|
| 48 |
Electronic health record tools to catalyse PrEP conversations
|
Ortblad, Katrina F
|
|
2019
|
|
10 |
p. e644-e645
|
artikel
|
| 49 |
Emergent HIV drug resistance in non-inferiority trials
|
Ripamonti, Diego
|
|
|
|
10 |
p. e632-e634
|
artikel
|
| 50 |
Engineered HIV antibody passes muster
|
Morris, Lynn
|
|
2019
|
|
10 |
p. e641-e642
|
artikel
|
| 51 |
Enhanced immigration enforcement in the USA and the transnational continuity of HIV care for Latin American immigrants in deportation proceedings
|
Page, Kathleen R
|
|
2018
|
|
10 |
p. e597-e604
|
artikel
|
| 52 |
Enhancing efforts to address infections
|
Luz, Paula M
|
|
2015
|
|
10 |
p. e406-e407
nvt p.
|
artikel
|
| 53 |
Estimating the impact of differentiated models for HIV care
|
Maskew, Mhairi
|
|
|
|
10 |
p. e628-e630
|
artikel
|
| 54 |
Expanding coverage of paediatric HIV testing
|
Chibwesha, Carla J
|
|
2016
|
|
10 |
p. e451-e453
nvt p.
|
artikel
|
| 55 |
Families matter: differentiated service delivery for HIV
|
Srivastava, Meena
|
|
2019
|
|
10 |
p. e646-e648
|
artikel
|
| 56 |
From sharing needles to unprotected sex: a new wave of HIV infections in Iran?
|
Leylabadlo, Hamed Ebrahimzadeh
|
|
2016
|
|
10 |
p. e461-e462
nvt p.
|
artikel
|
| 57 |
Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990–2019, for 204 countries and territories: the Global Burden of Diseases Study 2019
|
|
|
|
|
10 |
p. e633-e651
|
artikel
|
| 58 |
Harm reduction for smokers living with HIV
|
Shuter, Jonathan
|
|
|
|
10 |
p. e652-e658
|
artikel
|
| 59 |
Has UNAIDS left the Middle East and north Africa behind?
|
Rizk, Nesrine A
|
|
|
|
10 |
p. e630-e632
|
artikel
|
| 60 |
Health systems software factors and their effect on the integration of sexual and reproductive health and HIV services
|
Mayhew, Susannah H
|
|
|
|
10 |
p. e711-e720
|
artikel
|
| 61 |
Heightened epidemic in men who have sex with men in Brazil
|
Hogg, Robert S
|
|
2016
|
|
10 |
p. e454-e455
nvt p.
|
artikel
|
| 62 |
HERO—providing support for those engaged in chemsex
|
Barmania, Sima
|
|
|
|
10 |
p. e677
|
artikel
|
| 63 |
HIV care continuum for key populations in Indonesia
|
Poudel, Krishna C
|
|
2018
|
|
10 |
p. e539-e540
|
artikel
|
| 64 |
HIV, chemsex, and the need for harm-reduction interventions to support gay, bisexual, and other men who have sex with men
|
Strong, Carol
|
|
|
|
10 |
p. e717-e725
|
artikel
|
| 65 |
HIV control in hyperendemic communities in east Africa
|
Zielinski-Gutierrez, Emily C
|
|
2019
|
|
10 |
p. e643-e644
|
artikel
|
| 66 |
HIV drug resistance in low-income and middle-income countries
|
Hamers, Raph L
|
|
2018
|
|
10 |
p. e588-e596
|
artikel
|
| 67 |
HIV incidence among people who inject drugs (PWIDs) in Ukraine: results from a clustered randomised trial
|
Booth, Robert E
|
|
2016
|
|
10 |
p. e482-e489
nvt p.
|
artikel
|
| 68 |
HIV-related CNS infections: translating DREAMM into reality
|
Meya, David B
|
|
|
|
10 |
p. e627-e628
|
artikel
|
| 69 |
HIV stigma is a barrier to achieving 90-90-90 in India
|
Ekstrand, Maria L
|
|
2018
|
|
10 |
p. e543-e545
|
artikel
|
| 70 |
HIV testing and human rights: the right to the right test
|
Nkengasong, John N
|
|
2016
|
|
10 |
p. e457-e458
nvt p.
|
artikel
|
| 71 |
HIV viral load messages should go viral in India
|
Isaakidis, Petros
|
|
2015
|
|
10 |
p. e414-e415
nvt p.
|
artikel
|
| 72 |
HIV viral suppression is key to healthy longevity
|
Kiplagat, Jepchirchir
|
|
|
|
10 |
p. e672-e673
|
artikel
|
| 73 |
Homosexuality law reform is just a first step for India
|
The Lancet HIV,
|
|
2018
|
|
10 |
p. e537
|
artikel
|
| 74 |
Household survey of HIV incidence in Rwanda: a national observational cohort study
|
Nsanzimana, Sabin
|
|
2017
|
|
10 |
p. e457-e464
|
artikel
|
| 75 |
How will we get there? How will we know?
|
Eaton, Jeffrey W
|
|
2017
|
|
10 |
p. e429-e430
|
artikel
|
| 76 |
Impact of combination HIV interventions on HIV incidence in hyperendemic fishing communities in Uganda: a prospective cohort study
|
Kagaayi, Joseph
|
|
2019
|
|
10 |
p. e680-e687
|
artikel
|
| 77 |
Impact of differentiated service delivery models on 12-month retention in HIV treatment in Mozambique: an interrupted time-series analysis
|
Uetela, Dorlim A Moiana
|
|
|
|
10 |
p. e674-e683
|
artikel
|
| 78 |
Implementation guidance needed for PrEP risk-prediction tools
|
Calabrese, Sarah K
|
|
2019
|
|
10 |
p. e649
|
artikel
|
| 79 |
Improvements in transition times through the HIV cascade of care among gay and bisexual men with a new HIV diagnosis in New South Wales and Victoria, Australia (2012–19): a longitudinal cohort study
|
van Santen, Daniela K
|
|
|
|
10 |
p. e623-e632
|
artikel
|
| 80 |
Improving services to tackle the syndemic of HIV and mental ill health
|
Nandi, Dhruva
|
|
|
|
10 |
p. e674
|
artikel
|
| 81 |
Incidence data do not count everyone
|
Negin, Joel
|
|
|
|
10 |
p. e603
|
artikel
|
| 82 |
Incidence data do not count everyone – Author's reply
|
Risher, Kathryn A
|
|
|
|
10 |
p. e603
|
artikel
|
| 83 |
Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies
|
Rutstein, Sarah E
|
|
|
|
10 |
p. e721-e730
|
artikel
|
| 84 |
INSTIs and weight gain in pregnancy
|
Bengtson, Angela M
|
|
|
|
10 |
p. e663-e665
|
artikel
|
| 85 |
Is it time to abandon single intervention cure trials?
|
Ananworanich, Jintanat
|
|
2015
|
|
10 |
p. e410-e411
nvt p.
|
artikel
|
| 86 |
Is monotherapy maintenance the way forward?
|
Calmy, Alexandra
|
|
2015
|
|
10 |
p. e402-e403
nvt p.
|
artikel
|
| 87 |
Is surgical preadmission an underused opportunity in HIV?
|
Acharya, Amish
|
|
2016
|
|
10 |
p. e459-e460
nvt p.
|
artikel
|
| 88 |
It is time to act on ageing
|
The Lancet HIV,
|
|
|
|
10 |
p. e599
|
artikel
|
| 89 |
Legal impediments to prevention
|
Davis, Sara L M
|
|
2016
|
|
10 |
p. e461-
1 p.
|
artikel
|
| 90 |
Liver disease in patients with HIV in sub-Saharan Africa
|
Cainelli, Francesca
|
|
2015
|
|
10 |
p. e412-e413
nvt p.
|
artikel
|
| 91 |
Lung cancer in people living with HIV
|
Januszewski, Adam P
|
|
|
|
10 |
p. e670-e672
|
artikel
|
| 92 |
Lymphomas included in the AIDS case definition: an update 30 years later
|
Vaccher, Emanuela
|
|
|
|
10 |
p. e635
|
artikel
|
| 93 |
Mainline—confronting chemsex in the Netherlands
|
Kirby, Tony
|
|
|
|
10 |
p. e678
|
artikel
|
| 94 |
Methadone treatment in primary care
|
Wu, Zunyou
|
|
2015
|
|
10 |
p. e408-e409
nvt p.
|
artikel
|
| 95 |
Mortality in HIV-infected women, heterosexual men, and men who have sex with men in Rio de Janeiro, Brazil: an observational cohort study
|
Coelho, Lara
|
|
2016
|
|
10 |
p. e490-e498
nvt p.
|
artikel
|
| 96 |
Navigating the AIDS crisis with open hearts
|
Hayward, Peter
|
|
|
|
10 |
p. e679
|
artikel
|
| 97 |
Need for robust and inclusive public health ethics review of the monitoring of HIV phylogenetic clusters for HIV prevention
|
Gilbert, Mark
|
|
2016
|
|
10 |
p. e461-
1 p.
|
artikel
|
| 98 |
No more Scott Counties
|
Beyrer, Chris
|
|
2018
|
|
10 |
p. e541-e542
|
artikel
|
| 99 |
Not your own story: the complexities of HIV disclosure in Ireland
|
Lucas, Cathy
|
|
|
|
10 |
p. e639
|
artikel
|
| 100 |
Optimising treatment in the test-and-treat strategy: what are we waiting for?
|
Phanuphak, Nittaya
|
|
2019
|
|
10 |
p. e715-e722
|
artikel
|
| 101 |
Paediatric HIV testing beyond the context of prevention of mother-to-child transmission: a systematic review and meta-analysis
|
Cohn, Jennifer
|
|
2016
|
|
10 |
p. e473-e481
nvt p.
|
artikel
|
| 102 |
Paediatric HIV: the unfinished business
|
Penazzato, Martina
|
|
2017
|
|
10 |
p. e425-e427
|
artikel
|
| 103 |
Paying tribute to a generation devastated by HIV/AIDS
|
Burki, Talha
|
|
|
|
10 |
p. e604
|
artikel
|
| 104 |
Populism threatens Brazil's HIV/AIDS response
|
Daniels, Joe Parkin
|
|
2019
|
|
10 |
p. e650-e651
|
artikel
|
| 105 |
Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study
|
Cepeda, Javier A
|
|
2018
|
|
10 |
p. e578-e587
|
artikel
|
| 106 |
PrEP: why are we waiting?
|
The Lancet HIV,
|
|
2015
|
|
10 |
p. e401-
1 p.
|
artikel
|
| 107 |
Prioritising the values of potential users to promote uptake of HIV pre-exposure prophylaxis
|
Traeger, Michael W
|
|
|
|
10 |
p. e690-e692
|
artikel
|
| 108 |
Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial
|
Paton, Nicholas I
|
|
2015
|
|
10 |
p. e417-e426
nvt p.
|
artikel
|
| 109 |
Public Health England's political end
|
The Lancet HIV,
|
|
|
|
10 |
p. e661
|
artikel
|
| 110 |
Putting people first in communication about HIV
|
The Lancet HIV,
|
|
|
|
10 |
p. e623
|
artikel
|
| 111 |
Reduction in mortality from HIV-related CNS infections in routine care in Africa (DREAMM): a before-and-after, implementation study
|
Mfinanga, Sayoki
|
|
|
|
10 |
p. e663-e673
|
artikel
|
| 112 |
Robust evidence of Bolsa Família Programme's benefits
|
Luz, Paula M
|
|
|
|
10 |
p. e669-e670
|
artikel
|
| 113 |
Russia's generalising HIV epidemic
|
The Lancet HIV,
|
|
2016
|
|
10 |
p. e449-
1 p.
|
artikel
|
| 114 |
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial
|
Lalezari, Jacob P
|
|
2015
|
|
10 |
p. e427-e437
nvt p.
|
artikel
|
| 115 |
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study
|
Baden, Lindsey R
|
|
|
|
10 |
p. e688-e698
|
artikel
|
| 116 |
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial
|
Gaudinski, Martin R
|
|
2019
|
|
10 |
p. e667-e679
|
artikel
|
| 117 |
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial
|
Sobieszczyk, Magdalena E
|
|
|
|
10 |
p. e653-e662
|
artikel
|
| 118 |
Second-line antiretroviral therapy: so much to be done
|
Assefa, Yibeltal
|
|
2017
|
|
10 |
p. e424-e425
|
artikel
|
| 119 |
Switching antiretrovirals in older patients
|
Gianotti, Nicola
|
|
2019
|
|
10 |
p. e640-e641
|
artikel
|
| 120 |
Tackling cancer risk in adolescents and young adults with HIV
|
Davidson, Alan
|
|
|
|
10 |
p. e601-e602
|
artikel
|
| 121 |
The cascade of HIV care among key populations in Indonesia: a prospective cohort study
|
Januraga, Pande Putu
|
|
2018
|
|
10 |
p. e560-e568
|
artikel
|
| 122 |
The doctor's dilemma and vaccine therapy for HIV
|
Crowell, Trevor A
|
|
2016
|
|
10 |
p. e450-e451
nvt p.
|
artikel
|
| 123 |
Transparency of participant incentives in HIV research
|
Brown, Brandon
|
|
2016
|
|
10 |
p. e456-e457
nvt p.
|
artikel
|
| 124 |
Treating the parts other doctors cannot reach
|
Stirrups, Robert
|
|
2018
|
|
10 |
p. e552
|
artikel
|
| 125 |
Treatment of HIV and HBV coinfection
|
Bani-Sadr, Firouzé
|
|
|
|
10 |
p. e624-e625
|
artikel
|
| 126 |
Trends and risk of lung cancer among people living with HIV in the USA: a population-based registry linkage study
|
Haas, Cameron B
|
|
|
|
10 |
p. e700-e708
|
artikel
|
| 127 |
UNAIDS departure leaves vacuum in leadership in MENA
|
Burki, Talha
|
|
|
|
10 |
p. e637
|
artikel
|
| 128 |
Use of electronic health record data and machine learning to identify candidates for HIV pre-exposure prophylaxis: a modelling study
|
Marcus, Julia L
|
|
2019
|
|
10 |
p. e688-e695
|
artikel
|
| 129 |
Vaginal dysbiosis and pre-exposure prophylaxis efficacy
|
van de Wijgert, Janneke
|
|
2017
|
|
10 |
p. e427-e429
|
artikel
|
| 130 |
Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial
|
|
|
2018
|
|
10 |
p. e553-e559
|
artikel
|
| 131 |
Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial
|
Price, Joan T
|
|
|
|
10 |
p. e605-e613
|
artikel
|
| 132 |
Would you like an HIV test?
|
The Lancet HIV,
|
|
2017
|
|
10 |
p. e423
|
artikel
|
| 133 |
Xpert HIV-1 point-of-care test for neonatal diagnosis of HIV in the birth testing programme of a maternity hospital: a field evaluation study
|
Technau, Karl-Günter
|
|
2017
|
|
10 |
p. e442-e448
|
artikel
|
| 134 |
25 years later: the revival of Angels in America
|
Kirby, Tony
|
|
2018
|
|
10 |
p. e550
|
artikel
|
Tijdschrift beschrijving